Fundraising Fox
/Companies
Sign in

Spine BioPharma

New York, US · Founded 2015 · Delaware corporation · 8 employees on LinkedIn · 4 known investors

Find your way into Spine BioPharma

Sign up to see every warm intro you have to Spine BioPharma

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Spine BioPharma team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Developing non-surgical, non-opioid therapies for degenerative disc disease through targeted peptide injection.

Biotech

Founders & leadership

Spine BioPharma was founded in 2015 by Marc R. Viscogliosi.

MRMarc R. Viscogliosi
Marc R. ViscogliosiFounder · Chairman & CEOMarc Viscogliosi is a medical device executive with over two decades of experience in company operations, capital raises, and regulatory strategy. He holds multiple issued medical device patents and has led products through FDA approvals and payer coverage processes.
FM
Fran MageeChief Technology Officerformer
JGJason Gallagher
Jason GallagherCCO & COO; Head of Strategy & Commercialization2023–2025Jason Gallagher is Chief Commercial Officer and Chief Operations Officer at Spine BioPharma, which develops non-surgical, non-opioid therapies for degenerative disc disease. He has over 20 years of experience in biopharma across startups, specialty therapeutics, rare disease, regenerative medicine, and large-cap pharmaceutical companies.

Board

JJ
John J. ViscogliosiBoard director
TB
Thomas Bumol, PhDBoard director
FC
Frank Cammisa, MDBoard director

Investors · 4

Cercano ManagementreportedBellevue

How we know: ryortho.com · Not right? Tell us

Also in the syndicate · 2

Pacira Biosciences, Inc.Viscogliosi Bros., LLC

Reported raises · per SEC filings

Form D private placements

$52.2M disclosed across 8 rounds · 2021–2026

▶$384.8KraisedJun 2026 · 3 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Fran MageeExecutive Officer
  • John J. ViscogliosiDirector
  • Thomas Bumol, PhDDirector
  • Marc R. ViscogliosiExecutive Officer, Director
  • Frank Cammisa, MDDirector
Offering amount
$8.5M
Amount sold
$384.8K
First sale
May 2026
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$13.5MraisedDec 2024 · 10 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Thomas Bumol, PhDDirector
  • Fran MageeExecutive Officer
  • Jason GallagherExecutive Officer
  • Marc R. ViscogliosiExecutive Officer, Director
  • Frank Cammisa, MDDirector
  • John J. ViscogliosiDirector
Offering amount
$23.5M
Amount sold
$13.5M
First sale
Sep 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.4MraisedOct 2023 · 3 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Frank Cammisa, MDDirector
  • Marc R. ViscogliosiExecutive Officer, Director
  • Fran MageeExecutive Officer
  • John J. ViscogliosiDirector
  • Thomas Bumol, PhDDirector
Offering amount
$15M
Amount sold
$2.4M
First sale
Oct 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.9MraisedAug 2023 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Frank Cammisa, MDDirector
  • Fran MageeExecutive Officer
  • John J. ViscogliosiDirector
  • Thomas Bumol, PhDDirector
  • Marc R. ViscogliosiExecutive Officer, Director
Offering amount
$13M
Amount sold
$1.9M
First sale
Aug 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$13MraisedFeb 2023 · 8 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Thomas Bumol, PhDDirector
  • John J. ViscogliosiDirector
  • Frank Cammisa, MDDirector
  • Marc R. ViscogliosiExecutive Officer, Director
  • Fran MageeExecutive Officer
Offering amount
$13M
Amount sold
$13M
First sale
Feb 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$13MraisedMar 2022 · 6 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Thomas Bumol, PhDDirector
  • John J. ViscogliosiDirector
  • Fran MageeExecutive Officer
  • Marc R. ViscogliosiExecutive Officer, Director
  • Frank Cammisa, MDDirector
Offering amount
$30.4M
Amount sold
$13M
First sale
Mar 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3MraisedApr 2021 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • LLC Viscogliosi Brothers,Executive Officer
  • Marc R. ViscogliosiExecutive Officer
  • John J ViscogliosiExecutive Officer
Offering amount
$3M
Amount sold
$3M
First sale
Apr 2021
Incorporated
Limited Liability Company, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5MraisedMar 2021 · 14 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • LLC Viscogliosi Brothers,Executive Officer
  • John J ViscogliosiExecutive Officer
  • Marc R. ViscogliosiExecutive Officer
Offering amount
$5M
Amount sold
$5M
Minimum investment
$25K
First sale
Mar 2021
Incorporated
Limited Liability Company, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Spine BioPharma Announces Topline Results from Phase 3 MODEL Trial For SB-01 (vicatertide) In Chronic Low Back Pain Associated with Degenerative Disc Diseasefinance.yahoo.com · Aug 2025Spine BioPharma Completes Series B Financing - BioSpacebiospace.com · Mar 2022

Frequently asked questions

What does Spine BioPharma do?
Developing non-surgical, non-opioid therapies for degenerative disc disease through targeted peptide injection.
Who founded Spine BioPharma?
Spine BioPharma was founded by Marc R. Viscogliosi in 2015.
Who are Spine BioPharma's investors?
Spine BioPharma's investors include Blindspot Ventures Management Co, Cercano Management.
How much funding has Spine BioPharma raised?
Spine BioPharma has disclosed $52.2M raised across 8 rounds.
Where is Spine BioPharma headquartered?
Spine BioPharma is headquartered in New York, US.